Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Insler, V.
Right arrow Articles by Levy, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Insler, V.
Right arrow Articles by Levy, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 4, No. suppl_1, pp. 47-51, 1989
© 1989 European Society of Human Reproduction and Embryology

The combined suppression/stimulation therapy in IVF–ET programmes: expectations and facts

Vaclav Insler1, Gad Potashnik, Eitan Lunenfeld, Israel Meizner and Joseph Levy

Division of Obstetrics and Gynaecology and Endocrine Laboratory, Soroka Medical Centre and Faculty of Health Sciences, Ben-Gurion University of the Negev Beer-Sheba, Israel

Correspondence: 1To whom correspondence should be addressed

The benefits of combined pituitary suppression/ovarian stimulation therapy in IVF-ET programmes could be avoiding an untimely LH secretion, synchronization of the ovarian response to stimulation, an increased number of ova obtained and embryos replaced and a higher pregnancy rate. The first two advantages can be considered as direct effects of the combined therapy, while the others result, at least partly, from the more aggressive use of gonadotrophins. The capability of combined GnRH analogue/gonadotrophin treatment to avoid failures due to premature luteinization of follicles seems to be unequivocal. In order to obtain a better synchronized ovarian response to stimulation, new treatment schemes, based on prolonged use of currently available agonists or on application of potent synthetic GnRH antag onists, will have to be developed. Basic studies concerning the presence and the extent of a direct effect of GnRH analogues upon ovarian function would also help in a better understanding and more efficient application of the combined suppression/stimulation therapy in IVF—ET programmes.

Key words: gonadotrophin therapy/gonadotrophin suppression/GnRH analogues/IVF—ET LH levels after GnRHa


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.